))
#071 $TLX in Hot Water Telix Faces SEC Heat Over Drug Development Disclosures
Manage episode 521970776 series 3678700
Content provided by SueWallSt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by SueWallSt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Telix Pharmaceuticals $TLX is facing a federal subpoena and a scorching class action lawsuit after allegedly misleading investors about its prostate cancer drug pipeline and FDA compliance. In this episode of Sue Wall Street, we dive into how missing trial data, shady supply chain claims, and a bombshell FDA rejection sent the stock tumbling. Ideal for biotech investors, legal watchers, and anyone tracking pharmaceutical accountability. Get the facts, not just the filings.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
71 episodes
Share
